Table 4 Prognostic value of FOXA1 index ≥1% in FMCs estimated by multivariate analysis (180 cases)

Disease-free interval

FOXA1 positivity

FOXA1 ≥ 1% versus < 1%

0.009

0.58

0.39–0.87

Pathologic tumor size

pT ≥ 20 mm versus < 20 mm

0.047

1.46

1.01–2.12

Distant metastasis

M1 versus M0–MX

< 0.0001

5.05

2.41–10.56

Overall survival

FOXA1 positivity

FOXA1 ≥ 1% versus < 1%

0.030

0.70

0.50–0.96

Pathologic tumor size

pT ≥ 20 mm versus < 20 mm

0.001

1.69

1.24–2.30

Distant metastasis

M1 versus M0–MX

0.005

2.82

1.36–5.82

Cancer-specific survival

FOXA1 positivity

FOXA1 ≥ 1% versus < 1%

0.032

0.65

0.44–0.96

Pathologic tumor size

pT ≥ 20 mm versus < 20 mm

0.004

1.69

1.18–2.42

Pathologic nodal stage

pN+ versus pN0–pNX

0.002

1.83

1.26–2.66

Distant metastasis

M1 versus M0–MX

0.001

3.47

1.66–7.23